2
|
Skrok MK, Tamborski S, Hepburn MS, Fang Q, Maniewski M, Zdrenka M, Szkulmowski M, Kowalewski A, Szylberg Ł, Kennedy BF. Imaging of prostate micro-architecture using three-dimensional wide-field optical coherence tomography. BIOMEDICAL OPTICS EXPRESS 2024; 15:6816-6833. [PMID: 39679405 PMCID: PMC11640564 DOI: 10.1364/boe.537783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/25/2024] [Revised: 10/04/2024] [Accepted: 10/08/2024] [Indexed: 12/17/2024]
Abstract
Prostate cancer is a global health issue that requires new diagnostic methods to provide accurate and precise visualization of prostate tissue on the micro-scale. Such methods have the potential to improve nerve-sparing surgery and to provide image guidance during prostate biopsy. In this feasibility study, we assess the potential of en face three-dimensional wide-field optical coherence tomography (OCT), covering a volumetric imaging field-of-view up to 46 × 46 × 1 mm3, to visualize micro-architecture in 18 freshly excised human prostate specimens. In each case, validation of contrast in OCT images is provided by co-registered wide-field histology images. Using this co-registration, we demonstrate that OCT can distinguish between healthy and cancerous glands at different stages, as well as visualize micro-architecture in the prostate, such as epineurium and perineurium in nerves and the tunica intima and tunica media in blood vessels.
Collapse
Affiliation(s)
- Marta K. Skrok
- Institute of Physics, Faculty of Physics, Astronomy and Informatics, Nicolaus Copernicus University in Toruń, 5 Grudziądzka St., 87-100 Toruń, Poland
| | - Szymon Tamborski
- Institute of Physics, Faculty of Physics, Astronomy and Informatics, Nicolaus Copernicus University in Toruń, 5 Grudziądzka St., 87-100 Toruń, Poland
| | - Matt S. Hepburn
- Institute of Physics, Faculty of Physics, Astronomy and Informatics, Nicolaus Copernicus University in Toruń, 5 Grudziądzka St., 87-100 Toruń, Poland
- Department of Electrical, Electronic and Computer Engineering, School of Engineering, The University of Western Australia, 35 Stirling Highway, Perth 6009, Western Australia, Australia
- BRITElab, Harry Perkins Institute of Medical Research, QEII Medical Centre Nedlands and Centre for Medical Research, The University of Western Australia, Perth, Western Australia 6009, Australia
| | - Qi Fang
- Department of Electrical, Electronic and Computer Engineering, School of Engineering, The University of Western Australia, 35 Stirling Highway, Perth 6009, Western Australia, Australia
- BRITElab, Harry Perkins Institute of Medical Research, QEII Medical Centre Nedlands and Centre for Medical Research, The University of Western Australia, Perth, Western Australia 6009, Australia
| | - Mateusz Maniewski
- Department of Obstetrics, Gynaecology and Oncology, Chair of Pathomorphology and Clinical Placentology, Collegium Medicum Jan Biziel University Hospital, 75 Ujejskiego St., Bydgoszcz 85-168, Poland
- Department of Tumor Pathology and Pathomorphology, Oncology Centre, Prof Franciszek Łukaszczyk Memorial Hospital, 2 Romanowskiej St., Bydgoszcz 85-796, Poland
| | - Marek Zdrenka
- Department of Tumor Pathology and Pathomorphology, Oncology Centre, Prof Franciszek Łukaszczyk Memorial Hospital, 2 Romanowskiej St., Bydgoszcz 85-796, Poland
| | - Maciej Szkulmowski
- Institute of Physics, Faculty of Physics, Astronomy and Informatics, Nicolaus Copernicus University in Toruń, 5 Grudziądzka St., 87-100 Toruń, Poland
| | - Adam Kowalewski
- Department of Tumor Pathology and Pathomorphology, Oncology Centre, Prof Franciszek Łukaszczyk Memorial Hospital, 2 Romanowskiej St., Bydgoszcz 85-796, Poland
- Center of Medical Sciences, University of Science and Technology, 7 Kaliskiego St., Bydgoszcz 85-796, Poland
| | - Łukasz Szylberg
- Department of Obstetrics, Gynaecology and Oncology, Chair of Pathomorphology and Clinical Placentology, Collegium Medicum Jan Biziel University Hospital, 75 Ujejskiego St., Bydgoszcz 85-168, Poland
- Department of Tumor Pathology and Pathomorphology, Oncology Centre, Prof Franciszek Łukaszczyk Memorial Hospital, 2 Romanowskiej St., Bydgoszcz 85-796, Poland
| | - Brendan F. Kennedy
- Institute of Physics, Faculty of Physics, Astronomy and Informatics, Nicolaus Copernicus University in Toruń, 5 Grudziądzka St., 87-100 Toruń, Poland
- Department of Electrical, Electronic and Computer Engineering, School of Engineering, The University of Western Australia, 35 Stirling Highway, Perth 6009, Western Australia, Australia
- BRITElab, Harry Perkins Institute of Medical Research, QEII Medical Centre Nedlands and Centre for Medical Research, The University of Western Australia, Perth, Western Australia 6009, Australia
| |
Collapse
|
4
|
Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, Boutros P, Fraser M, Bristow RG, van der Kwast T, Orain M, Brisson H, Benzerdjeb N, Hovington H, Bergeron A, Fradet Y, Têtu B, Saad F, Leblond F, Trudel D. Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. PLoS Med 2020; 17:e1003281. [PMID: 32797086 PMCID: PMC7428053 DOI: 10.1371/journal.pmed.1003281] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Accepted: 07/20/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Prostate cancer (PC) is the most frequently diagnosed cancer in North American men. Pathologists are in critical need of accurate biomarkers to characterize PC, particularly to confirm the presence of intraductal carcinoma of the prostate (IDC-P), an aggressive histopathological variant for which therapeutic options are now available. Our aim was to identify IDC-P with Raman micro-spectroscopy (RμS) and machine learning technology following a protocol suitable for routine clinical histopathology laboratories. METHODS AND FINDINGS We used RμS to differentiate IDC-P from PC, as well as PC and IDC-P from benign tissue on formalin-fixed paraffin-embedded first-line radical prostatectomy specimens (embedded in tissue microarrays [TMAs]) from 483 patients treated in 3 Canadian institutions between 1993 and 2013. The main measures were the presence or absence of IDC-P and of PC, regardless of the clinical outcomes. The median age at radical prostatectomy was 62 years. Most of the specimens from the first cohort (Centre hospitalier de l'Université de Montréal) were of Gleason score 3 + 3 = 6 (51%) while most of the specimens from the 2 other cohorts (University Health Network and Centre hospitalier universitaire de Québec-Université Laval) were of Gleason score 3 + 4 = 7 (51% and 52%, respectively). Most of the 483 patients were pT2 stage (44%-69%), and pT3a (22%-49%) was more frequent than pT3b (9%-12%). To investigate the prostate tissue of each patient, 2 consecutive sections of each TMA block were cut. The first section was transferred onto a glass slide to perform immunohistochemistry with H&E counterstaining for cell identification. The second section was placed on an aluminum slide, dewaxed, and then used to acquire an average of 7 Raman spectra per specimen (between 4 and 24 Raman spectra, 4 acquisitions/TMA core). Raman spectra of each cell type were then analyzed to retrieve tissue-specific molecular information and to generate classification models using machine learning technology. Models were trained and cross-validated using data from 1 institution. Accuracy, sensitivity, and specificity were 87% ± 5%, 86% ± 6%, and 89% ± 8%, respectively, to differentiate PC from benign tissue, and 95% ± 2%, 96% ± 4%, and 94% ± 2%, respectively, to differentiate IDC-P from PC. The trained models were then tested on Raman spectra from 2 independent institutions, reaching accuracies, sensitivities, and specificities of 84% and 86%, 84% and 87%, and 81% and 82%, respectively, to diagnose PC, and of 85% and 91%, 85% and 88%, and 86% and 93%, respectively, for the identification of IDC-P. IDC-P could further be differentiated from high-grade prostatic intraepithelial neoplasia (HGPIN), a pre-malignant intraductal proliferation that can be mistaken as IDC-P, with accuracies, sensitivities, and specificities > 95% in both training and testing cohorts. As we used stringent criteria to diagnose IDC-P, the main limitation of our study is the exclusion of borderline, difficult-to-classify lesions from our datasets. CONCLUSIONS In this study, we developed classification models for the analysis of RμS data to differentiate IDC-P, PC, and benign tissue, including HGPIN. RμS could be a next-generation histopathological technique used to reinforce the identification of high-risk PC patients and lead to more precise diagnosis of IDC-P.
Collapse
Affiliation(s)
- Andrée-Anne Grosset
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Pathology and Cellular Biology, Université de Montréal, Montreal, Quebec, Canada
| | - Frédérick Dallaire
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Computer Engineering and Software Engineering, Polytechnique Montréal, Montreal, Quebec, Canada
| | - Tien Nguyen
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Engineering Physics, Polytechnique Montréal, Montreal, Quebec, Canada
| | - Mirela Birlea
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - Jahg Wong
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - François Daoust
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Engineering Physics, Polytechnique Montréal, Montreal, Quebec, Canada
| | - Noémi Roy
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - André Kougioumoutzakis
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - Feryel Azzi
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - Kelly Aubertin
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - Samuel Kadoury
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Computer Engineering and Software Engineering, Polytechnique Montréal, Montreal, Quebec, Canada
| | - Mathieu Latour
- Department of Pathology and Cellular Biology, Université de Montréal, Montreal, Quebec, Canada
- Department of Pathology, Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
| | - Roula Albadine
- Department of Pathology and Cellular Biology, Université de Montréal, Montreal, Quebec, Canada
- Department of Pathology, Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
| | - Susan Prendeville
- Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada
| | - Paul Boutros
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Department of Human Genetics, University of California, Los Angeles, Los Angeles, California, United States of America
- Department of Urology, University of California, Los Angeles, Los Angeles, California, United States of America
- Institute for Precision Health, University of California, Los Angeles, Los Angeles, California, United States of America
- Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, United States of America
| | - Michael Fraser
- Informatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Rob G. Bristow
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | | | - Michèle Orain
- Oncology Division, Centre de recherche du Centre hospitalier universitaire de Québec–Université Laval, Quebec City, Quebec, Canada
- Centre de recherche sur le cancer, Université Laval, Quebec City, Quebec, Canada
| | - Hervé Brisson
- Oncology Division, Centre de recherche du Centre hospitalier universitaire de Québec–Université Laval, Quebec City, Quebec, Canada
- Centre de recherche sur le cancer, Université Laval, Quebec City, Quebec, Canada
| | - Nazim Benzerdjeb
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
- Oncology Division, Centre de recherche du Centre hospitalier universitaire de Québec–Université Laval, Quebec City, Quebec, Canada
- Centre de recherche sur le cancer, Université Laval, Quebec City, Quebec, Canada
| | - Hélène Hovington
- Oncology Division, Centre de recherche du Centre hospitalier universitaire de Québec–Université Laval, Quebec City, Quebec, Canada
- Centre de recherche sur le cancer, Université Laval, Quebec City, Quebec, Canada
| | - Alain Bergeron
- Oncology Division, Centre de recherche du Centre hospitalier universitaire de Québec–Université Laval, Quebec City, Quebec, Canada
- Centre de recherche sur le cancer, Université Laval, Quebec City, Quebec, Canada
- Department of Surgery, Université Laval, Quebec City, Quebec, Canada
| | - Yves Fradet
- Oncology Division, Centre de recherche du Centre hospitalier universitaire de Québec–Université Laval, Quebec City, Quebec, Canada
- Centre de recherche sur le cancer, Université Laval, Quebec City, Quebec, Canada
- Department of Surgery, Université Laval, Quebec City, Quebec, Canada
| | - Bernard Têtu
- Oncology Division, Centre de recherche du Centre hospitalier universitaire de Québec–Université Laval, Quebec City, Quebec, Canada
- Centre de recherche sur le cancer, Université Laval, Quebec City, Quebec, Canada
| | - Fred Saad
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - Frédéric Leblond
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Engineering Physics, Polytechnique Montréal, Montreal, Quebec, Canada
| | - Dominique Trudel
- Centre de recherche du Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
- Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Pathology and Cellular Biology, Université de Montréal, Montreal, Quebec, Canada
- Department of Pathology, Centre hospitalier de l’Université de Montréal, Montreal, Quebec, Canada
| |
Collapse
|
5
|
Swaan A, Muller BG, Wilk LS, Almasian M, Zwartkruis ECH, Rozendaal LR, de Bruin DM, Faber DJ, van Leeuwen TG, van Herk MB. En-face optical coherence tomography for the detection of cancer in prostatectomy specimens: Quantitative analysis in 20 patients. JOURNAL OF BIOPHOTONICS 2020; 13:e201960105. [PMID: 32049426 DOI: 10.1002/jbio.201960105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Revised: 01/10/2020] [Accepted: 01/27/2020] [Indexed: 06/10/2023]
Abstract
The increase histopathological evaluation of prostatectomy specimens rises the workload on pathologists. Automated histopathology systems, preferably directly on unstained specimens, would accelerate the pathology workflow. In this study, we investigate the potential of quantitative analysis of optical coherence tomography (OCT) to separate benign from malignant prostate tissue automatically. Twenty fixated prostates were cut, from which 54 slices were scanned by OCT. Quantitative OCT metrics (attenuation coefficient, residue, goodness-of-fit) were compared for different tissue types, annotated on the histology slides. To avoid misclassification, the poor-quality slides, and edges of annotations were excluded. Accurate registration of OCT data with histology was achieved in 31 slices. After removing outliers, 56% of the OCT data was compared with histopathology. The quantitative data could not separate malignant from benign tissue. Logistic regression resulted in malignant detection with a sensitivity of 0.80 and a specificity of 0.34. Quantitative OCT analysis should be improved before clinical use.
Collapse
Affiliation(s)
- Abel Swaan
- Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Berrend G Muller
- Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Leah S Wilk
- Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Mitra Almasian
- Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Evita C H Zwartkruis
- Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - L Rence Rozendaal
- Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Daniel M de Bruin
- Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Dirk J Faber
- Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Ton G van Leeuwen
- Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Marcel B van Herk
- Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- Institute of Cancer Sciences, University of Manchester, Manchester, UK
- Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|